Mesoblast Limited is a biopharmaceutical company based in Melbourne, Australia, primarily focused on developing cell-based medicines. Founded in 2004, the company's mission is to provide treatments for severe and life-threatening inflammatory diseases, cardiovascular conditions, and back pain. Utilising its proprietary technology platform, Mesoblast develops off-the-shelf (allogeneic) cell products that are sourced from adult bone marrow donors.

Mesoblast has established a strong and diverse portfolio of product candidates. The company's lead product candidate, remestemcel-L, is currently under investigation for the treatment of various diseases including acute graft versus host disease and acute respiratory distress syndrome due to COVID-19. The company aims to make significant contributions to patient health through a focus on critical unmet medical needs.

Connect